PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist in the anaesthetised dog model of bronchoconstriction Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
Compound X – an inhaled β2 agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Potency and duration of action of R,R-glycopyrrolate (RRG) on acetylcholine (ACh) induced bronchoconstriction as compared to tiotropium (TIO) in unrestrained conscious mice Source: Eur Respir J 2005; 26: Suppl. 49, 217s Year: 2005
The in vitro biology of PF-00610355 – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
The in-vitro pharmacology of PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Nebulized bimosiamose – anti-inflammatory pan-selectin antagonist for the treatment of COPD Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Effects of intratracheal pf-00610355, an inhaled β2 adrenoceptor agonist, in anaesthetised animals Source: Annual Congress 2009 - New bronchodilators Year: 2009
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Use of multifactor-dimensionality reduction model predicting bronchodilator response by inhaled short-acting beta 2 agonist Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist Source: Annual Congress 2009 - New bronchodilators Year: 2009
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
What predicts short-acting beta agonist (SABA) monotherapy use in children? Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2 -adrenoreceptor agonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Effect of long-acting muscarinic antagonist (LAMA) on 24-hour physical behaviours in COPD Source: Virtual Congress 2020 – Reviews and novel insights into pulmonary rehabilitation Year: 2020
The effect of topical ophthalmic timolol in patients treated for COPD with inhaled beta adrenergic agonist albuterol Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006